Substudy 02C
Stadium/Indikation inkl. Kurzinfo
Melanom – 1st line
Resezierbares Stadium IIIB-IIID
Neoadjuvante Therapie
Anti-PD1 + anti-TIGIT vs Anti-PD1 + oncolytische Virotherapie vs Anti-PD1 + Anschliessende adjuvante anti-PD1 Therapie
Kurztitel
Merck MK3475
Substudy 02C
(UmbrellaTrial)
NCT04303169
Offizieller Titel
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C